This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
5a3u
From Proteopedia
| Line 13: | Line 13: | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| - | + | As part of the cellular adaptation to limiting oxygen availability in animals, the expression of a large set of genes is activated by the upregulation of the hypoxia-inducible transcription factors (HIFs). Therapeutic activation of the natural human hypoxic response can be achieved by the inhibition of the hypoxia sensors for the HIF system, i.e. the HIF prolyl-hydroxylases (PHDs). Here, we report studies on tricyclic triazole-containing compounds as potent and selective PHD inhibitors which compete with the 2-oxoglutarate co-substrate. One compound (IOX4) induces HIFalpha in cells and in wildtype mice with marked induction in the brain tissue, revealing that it is useful for studies aimed at validating the upregulation of HIF for treatment of cerebral diseases including stroke. | |
| - | Selective | + | Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain.,Chan MC, Atasoylu O, Hodson E, Tumber A, Leung IK, Chowdhury R, Gomez-Perez V, Demetriades M, Rydzik AM, Holt-Martyn J, Tian YM, Bishop T, Claridge TD, Kawamura A, Pugh CW, Ratcliffe PJ, Schofield CJ PLoS One. 2015 Jul 6;10(7):e0132004. doi: 10.1371/journal.pone.0132004., eCollection 2015. PMID:26147748<ref>PMID:26147748</ref> |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
Revision as of 08:11, 22 July 2015
HIF prolyl hydroxylase 2 (PHD2/EGLN1) in complex with 6-(5-oxo-4-(1H- 1,2,3-triazol-1-yl)-2,5-dihydro-1H-pyrazol-1-yl)nicotinic acid
| |||||||||||
Categories: Chowdhury, R | Gomez-Perez, V | Schofield, C J | 2-oxoglutarate | Ankyrin repeat domain | Ard | Asparaginyl/ aspartyl hydroxylase | Beta-hydroxylation | Cell structure | Development | Dioxygenase | Dna-binding | Dsbh | Egln | Facial triad | Helix-loop-helix-beta | Hif | Hif prolyl hydroxylase domain 2 | Hypoxia | Hypoxia-inducible factor | Iron | Metal-binding | Non-heme | Oxidoreductase | Oxygenase | Phd2 | Phosphorylation | S-nitrosylation | Signaling | Transcription | Transcription activator/inhibitor | Transcription and epigenetic regulation
